Selegiline Drug Profile

Boxed warning

Suicidality (transdermal patch for depression)
Serotonin syndrome risk with serotonergic drugs

Clinical alerts

Boxed warning

2 boxed warnings

Serotonergic

Serotonin syndrome risk when combined with other serotonergic drugs

Mechanism of action

Selectively inhibits MAO-B, increasing dopamine availability in striatum

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Major Depressive Disorder (MDD)
·MDD
·Parkinson's Disease
·Ménière's Disease
·Cognition Disorders

Interactions

No curated interaction pairs are recorded for Selegiline. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nausea
Dizziness
Insomnia
Orthostatic hypotension
Headache

Food, alcohol & herbal

Food

Oral: low tyramine diet at high doses; Patch: tyramine restriction at higher doses

Alcohol · moderate

May potentiate effects

Herbal

St. John's Wort (major) — Risk of serotonin syndrome

Pharmacokinetics

Half-life: 10 hours (metabolites 18-25 hours)
Protein binding: 85%
Metabolised by: CYP2B6, CYP2C19, CYP3A4

Pregnancy & lactation

Not recorded for Selegiline. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.